These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19955938)

  • 21. Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships.
    Brandt GE; Schmidt MD; Prisinzano TE; Blagg BS
    J Med Chem; 2008 Oct; 51(20):6495-502. PubMed ID: 18816111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.
    Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X
    Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
    Wan J; Shi F; Xu Z; Zhao M
    Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gedunin, a limonoid from Xylocarpus granatum, inhibits the growth of CaCo-2 colon cancer cell line in vitro.
    Uddin SJ; Nahar L; Shilpi JA; Shoeb M; Borkowski T; Gibbons S; Middleton M; Byres M; Sarker SD
    Phytother Res; 2007 Aug; 21(8):757-61. PubMed ID: 17450509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.
    Shinagawa A; Yoshida Y; Kurokawa T; Horiuchi Y; Tsuyoshi H; Orisaka M; Sawamura Y; Kleinman HK; Kotsuji F
    Int J Oncol; 2011 Dec; 39(6):1359-64. PubMed ID: 21935568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis.
    Yang X; Zhang L; Xie L
    Med Sci Monit; 2018 Jun; 24():3863-3872. PubMed ID: 29880787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
    Paul BT; Blanchard Z; Ridgway M; ElShamy WM
    Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
    Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
    FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin.
    Yoshida Y; Kurokawa T; Nishikawa Y; Orisa M; Kleinman HK; Kotsuji F
    Int J Oncol; 2008 Mar; 32(3):673-81. PubMed ID: 18292945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
    Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
    Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
    Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
    J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.